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Abstract
PARP-1 is a nuclear enzyme that plays an important role in DNA repair, recombination, proliferation and the genome
stability. The PARP-1 Val762Ala polymorphism has been associated with increased risk of developing cancers of the
prostate, esophagus and lung. The aim of this study was to determine whether the PARP-1 Val762Ala polymorphism is
associated with the risk of cervical carcinoma. MA-PCR was used to genotype the PARP-1 Val762Ala polymorphism in 539
women with cervical carcinoma, 480 women with CIN and 800 controls. The genotyping method was confirmed by the DNA
sequencing analysis. The PARP-1 Val762Ala polymorphism was not associated with the risk of CIN. However, women
carrying the PARP-1 Ala762Ala genotype were significantly susceptible to cervical carcinoma (OR: 2.70, 95% CI: 1.47–3.70),
and the similar results were also found in squamous cell carcinoma (OR: 2.56, 95% CI: 1.47–3.70). In HPV positive population,
the PARP-1 Ala762Ala genotype was also associated with increased risk of cervical carcinoma (OR: 5.56, 95% CI: 2.08–14.3).
Our results indicate that the PARP-1 Ala762Ala genotype increases the risk of cervical carcinoma.
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Introduction
Cervical carcinoma is one of the most common malignant
diseases among women with nearly 500 000 women developing
this disease each year [1,2]. Cervical cancer is thought to develop
through a multistep process involving virus, tumor suppressor
genes, proto-oncogenes and immunological factors [3,4]. It is well
recognized that specific oncogenic human papillomaviruses(HPVs)
are primary etiologic factor in cervical cancer [5,6]. However, only
a small fraction of HPV-infected lesions progress to cervical cancer
or its precursor lesion cervical intraepithelial neoplasia(CIN),
suggesting that other genetic factors may be involved in these
processes [7–9].
DNA repair pathways exist in all cells for maintaining genome
integrity [10], and mutations within these pathways can result in
cancer [11]. Poly(ADP-ribose) polymerase 1(PARP-1) is a DNA
strand break-sensing protein, and its activation is one of the early
responses to DNA damage [12]. PARP-1 gene localizes to
chromosome 1q41–42, consists of 23 exons and spans 47.3 kb
[12]. It encodes a multifunctional nuclear protein, which consists
of an N-terminal DNA binding domain, a central auto-modifica-
tion domain and a C-terminal catalytic domain [13]. PARP-1
catalyzes poly(ADP-ribosyl)ation, an immediate DNA-damage
dependent post-translational modification of itself, histones and
other nuclear proteins, which is believed to play a multifunctional
role in various cellular processes, including DNA-damage detec-
tion and repair, cell death pathways and mitotic apparatus
function [14]. Research found that PARP-1
2/2 mice show a
higher susceptibility to carcinogenesis induced by alkylating
agents(9). There are many identified single nucleotide polymor-
phism(SNP) in the PARP-1 gene, and some of which are reported
to be implicated in carcinogenesis [15–18]. Of note, the SNP of
PARP-1 Val762Ala (GTG/GCG) was associated with increased
risk of various cancers [16,17,19].
To the best of our knowledge, there is still no research about the
association between the SNP of PARP-1 Val762Ala(GTG/GCG)
and cervical carcinoma. Therefore, in the current population-
based case-control study, we investigated the genotype distribu-
tions of the PARP-1 Val762Ala(GTG/GCG) in patients with
cervical carcinoma or CIN.
Materials and Methods
Study Population
All 1019 patients (including 539 cases cancer and 480 cases
CIN) and 800 controls were unrelated ethnic Chinese women
from Zhejiang Province. Of the 539 cases cancer was consisted of
489 squamous carcinoma, 47 adenocarcinoam, 1 undifferentiated
carcinoma, 2 carcinosarcoma; FIGO stage Ia 53 cases, Ib 213
cases, IIa 133 cases, IIb 83cases, III 48 cases, IV 9 cases. Of the
480 cases CIN was consisted of 70 low grade cervical intraepi-
thelial lesion(CIN 1), 410 high grade cervical intraepithelial
lesion(CIN 2/3: 162 CIN 2, 248 CIN 3). The median ages of
the cancer, CIN and control women were 45 (range, 25–81), 39
(range, 21–69) and 40.5 (range, 20–79) years, respectively. In the
Hangzhou district, Patients with histologically confirmed primary
cervical carcinoma or cervical dysplasia (CIN) at the Women’s
Hospital School of Medicine at Zhejiang University and the
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outside of Hangzhou, a collaborative network of gynecological
oncology teams in three areas (Lishui, Wenzhou and Shaoxing) of
Zhejiang Province was established to identify new cases of cervical
cancer or CIN at local hospitals between June 2004 and May
2006. The diagnosis date and tumor histology were recorded for
all of the women, and there were no age, stage, histology, or prior
therapy restrictions. During the same period, controls were
randomly selected from healthy women seen for gynecologic
examinations at the Women’s Hospital School of Medicine at
Zhejiang University. Control selection criteria included no positive
cytological findings (TCT: Thinprep cytologic test), no history of
cancer and immune disease, age matching to the patients and
residence in Zhejiang Province during the gynecological exami-
nation. After providing signed informed consent, participants
responded to a standard questionnaire about their sexual and
reproductive history, including the number of sexual partners, the
age at first intercourse, the age at first full-term pregnancy, parities
(including full-term pregnancy and abortion at or after 28 weeks)
and oral contraception used history. The study was approved by
the local Medical Ethics Committees, and informed consent was
obtained from all women included in the study(No. 2004002).
The blood samples of both patients and controls were collected.
Of these, 689 patients (264 with cervical carcinoma and 425 with
CIN) and 410 controls agreed to provide cervix brush-off samples
for detection of HPV. The median ages of these HPV detecting
cancer, CIN and control group were 42 (range, 25–76), 39 (range,
21–64) and 43 (range, 20–79) years, respectively.
DNA extraction and Genotyping
Genomic DNA was extracted from the blood with phenol/
chloroform and precipitated with cold ethanol. All genomic DNA
samples were dissolved in water and stored at 220uC.
The SNP of PARP-1 Val762Ala(GTG/GCG) was determined
by Modified polymerase chain reaction-mismatch amplifica-
tion(MA-PCR). The two forward primers were 59-
TGCTCCTCCAGGCCAAGCT-39and 59-
TGCTCCTCCAGGCCAAGCC-39, which differ in only the last
base, and the reverse primer was 59-GAAACGCC-
CAAAGGTTCT-39. The PCR product length was 330 bp.
Table 1. Frequency distribution of selected characteristics by case control status.
Variable Control(%),total=800 CIN(%),total=480 x
2* P Carcinoma(%),total=539 x
2*P
Age #40 400 (50.0) 304(63.3) 21.549 ,0.001 216(40.1) 12.772 ,0.001
.40 400(50.0) 176(36.7) 323(59.9)
Number of sexual
partners
#1 642(80.3) 381(79.4) 0.143 0.719 422(78.3) 0.756 0.408
.1 158(19.7) 99(20.6) 117(21.7)
Age at the first
intercourse
#20 years 236(29.5) 153(31.9) 0.800 0.380 174(32.3) 1.173 0.304
.20 years 564(70.5) 327(68.1) 365(67.7)
Number of parities #3 361(45.1) 186(36.7) 4.909 0.030 181(33.6) 17.813 ,0.001
.3 439(54.9) 294(63.3) 358(66.4)
Age at the first birth #22years 155(19.4) 105(21.9) 1.051 0.315 120(22.3) 1.646 0.214
.22 years 645(80.6) 375(78.1) 419(77.7)
Smoking status smoker 2(0.3) 2(0.4) 0.268 0.633 4(0.7) 1.748 0.224
nonsmoker 798(99.7) 478(99.6) 535(99.3)
HR-HPV infection Positive 127(31.0) 367(86.4) 264.876 ,0.001 233(88.3) 211.764 ,0.001
Negative 283(69.0) 58(13.6) 31(11.7)
oral contraceptive Yes 14(1.8) 10(2.1) 0.181 0.675 12(2.2) 0.384 0.550
No 786(98.3) 470(97.9) 527(97.8)
*Two-sided x
2 test.
doi:10.1371/journal.pone.0037446.t001
Table 2. Analysis of association between the polymorphisms and risk of CIN.
Genotypes* Control(%),total=800 CIN 1(%),total=70
adjusted
OR**(95% CI) P CIN 2/3(%),total=410
adjusted
OR**(95% CI) P
TT 257(32.1) 22(31.4) 1 126(30.7) 1
TC 475(59.4) 42(60.0) 1.03(0.60–1.77) 0.906 249(60.7) 1.07(0.82–1.39) 0.617
CC 68(8.5) 6(8.6) 1.03(0.40–2.64) 0.950 35(8.5) 1.05(0.66–1.66) 0.836
TC or CC 543(67.9) 48(68.6) 1.03(0.61–1.75) 0.905 284(69.2) 1.07(0.83–1.38) 0.622
*CC: PARP-1 Ala762Ala(GCG/GCG); TC: Val762Ala(GTG/GCG); TT: Val762Val(GTG/GTG).
**all P-values adjusted for age.
doi:10.1371/journal.pone.0037446.t002
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of genomic DNA, 5.0 pmol of each primer, 0.2 mM of each
deoxynucleoside triphosphate and 1.0 units of Taq DNA
polymerase (Sangon, Shanghai, China). PCR was carried out
under the following conditions: an initial denaturation at 94uC for
5 min, followed by 35 cycles of 94uC for 30 s, 57uC for 30 s, and
72uC for 45 s, and a final elongation step of 72uC for 10 min. The
PCR products were examined by 1% agarose gel electrophoresis,
stained with ethidium bromide and visualized with a Typhoon
TM
9410 Imaging System (GE Healthcare, USA). To examine the
reproducibility of the results, all samples were tested twice by two
technicians and the results agreed for all masked duplicate sets.
The results reproducibility of two technicians was one hundred
percent.
To confirm the specificity of the MA-PCR for the polymor-
phisms, 20% of the samples were randomly selected (n=200) and
sequenced in a blinded manner. The forward and reverse primers
for PCR sequencing were 59-CCACCTGGGTGAGTCTGTCT-
39 and 59-AGGCCTGACCCTGTTACCTT-39, which produce a
212 bp fragment. Dye terminator DNA sequencing was per-
formed in both directions using a BigDye Terminator Kit (Applied
Biosystems, Foster City, CA, USA) at the ABI PRISM 3100
Genetic Analyzer (Applied Biosystems). PCR products and dye-
terminated products were purified by ethanol/sodium acetate
precipitation. Comparison of the two methods of analyzing
polymorphisms did not identify any discordant pairs. These
indicated that the MA-PCR specificity rate of detecting PARP-1
Val762Ala (GTG/GCG) was one hundred percent.
HPV detection
HPV infection was identified using the Hybrid Capture II(HC
II) assay (Digene Diagnostics Inc., Gaitherburg, MD, USA) using
probe B, which contains a pool of full-length RNA probes specific
for HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68.
Cervical sampling for HPV DNA was performed with the Digene
Cervical Sampler, and the tests were classified according to the
relative light units/positive control ratio, measured as the relative
light units of the specimen divided by the mean relative light units
of two positive controls.
Table 3. According to HPV infection status(HPV positive) stratified analysis of the association between genotypes and risk of
cervical carcinoma and CIN.
Genotypes* Control(%),total=127 CIN(%),total=367
adjusted
OR**(95% CI) P Carcinomas(%),total=233
adjusted OR**
(95% CI) P
TT 46(36.2) 115(31.3) 1.00 41(17.6) 1.00
TC 76(59.8) 225(61.3) 1.18(0.77–1.82) 0.440 125(53.6) 1.85(1.11–3.07) 0.018
CC 5(3.9) 27(7.4) 2.17(0.78–5.88) 0.137 67(28.8) 5.56(2.08–14.30) 0.001
TC or CC 81(63.8) 252(68.7) 1.24(0.82–1.90) 0.312 192(82.4) 2.66(1.62–4.36) ,0.001
*CC: PARP-1 Ala762Ala(GCG/GCG); TC: Val762Ala(GTG/GCG); TT: Val762Val(GTG/GTG).
**all P-values adjusted for age.
doi:10.1371/journal.pone.0037446.t003
Table 4. According to different sexual or reproductive histories subgroup stratified analyses between the genotypes and CIN risk.
High risk exposure Controls(%) CIN cases(%) Adjusted OR**(95% CI)P
TT* TC or CC* TT* TC or CC*
Number of sexual partners
#1 204(31.8) 438(68.2) 123(32.3) 258(67.7) 0.98(0.75–1.28) 0.866
.1 53(33.5) 105(66.5) 25(25.3) 74(74.7) 1.49(0.85–2.62) 0.161
Age at the first intercourse
#20 years 73(30.9) 163(69.1) 50(32.7) 103(67.3) 0.92(0.60–1.43) 0.717
.20 years 184(32.6) 380(67.4) 98(30.0) 229(70.0) 1.13(0.84–1.52) 0.412
Number of parities
#3 118(32.7) 243(67.3) 63(33.9) 123(66.1) 0.95(0.65–1.38) 0.781
.3 139(31.7) 300(68.3) 84(28.7) 209(71.3) 1.15(0.83–1.59) 0.389
Age at the first parity
#22 years 45(29.0) 110(71.0) 35(33.7) 69(66.3) 0.81(0.47–1.38) 0.430
.22 years 212(32.9) 433(67.1) 112(29.9) 262(70.1) 1.15(0.87–1.51) 0.335
Oral contraceptive
Yes 3(21.4) 11(78.6) 2(20.0) 8(80.0) 1.09(0.15–8.12) 0.932
No 254(32.3) 532(67.7) 146(31.1) 324(68.9) 1.06(0.83–1.36) 0.645
*CC: PARP-1 Ala762Ala(GCG/GCG); TC: Val762Ala(GTG/GCG); TT: Val762Val(GTG/GTG).
**all P-values adjusted for age.
doi:10.1371/journal.pone.0037446.t004
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Differences in frequencies of the genotypes and alleles between
the cases of cervical carcinoma or CIN and controls were
evaluated by the chi-square (x
2) test. Logistic regressions were
applied to calculate the odds ratio(OR) and 95% confidence
interval(CI), for the association between the genotypes and risk of
cervical carcinoma. All statistical analyses were carried out using
Statistical Package for Social Science software, version 11.5 (SPSS,
Chicago, IL).
Results
Subject characteristics
The demographic and clinical characteristics of patients and
controls are presented in Table 1. We analyzed 1019 patients (539
with cervical carcinoma and 480 with CIN) and 800 controls.
There were no statistically significant differences between patients
and controls in terms of number of sexual partners, age at the first
intercourse, age at the first birth, smoking status and oral
contraception used history. However, compared with controls,
patients with CIN had a higher proportion of subjects less than 40
years of age (63.3% versus 50.0% in controls, P,0.001), while
patients with cervical carcinoma had a lower proportion of
subjects less than 40 years of age (40.1% versus 50.0% in controls,
P,0.001). The proportion of subjects with the number of parities
(.3) in both cervical carcinoma and CIN patients is more than
that in controls (P,0.05). In addition, HPV infection rate was
31.0% in controls, 86.4% in patients with CIN, 88.3% in patients
with cervical carcinoma, respectively, indicating that higher HPV
infection rate in patients (P,0.001).
Polymorphism of PARP-1 and the risk of CIN
All genotypic distributions were consistent with that expected in
the Hardy–Weinberg model (x
2=4.571, P=0.102). Table 2
showed that the frequency of the PARP-1 Ala762Ala(GCG/
GCG), Val762Ala(GTG/GCG) and Val762Val(GTG/GTG)
genotypes were 8.6%, 60.0% and 31.4% in patients with CIN 1,
and 8.5%,60.7%,30.7% in patients with CIN 2/3, which was not
different with that in controls (8.5%, 59.4%, 32.1%). Also, in the
HPV positive subgroup, there was no difference in the genotypic
distribution of PARP-1 Val762Ala(GTG/GCG) between controls
and patients with CIN (Table 3). Likewise, patients with CIN had
the same frequency of the PARP-1 Ala762Ala(GCG/GCG),
Val762Ala(GTG/GCG) and Val762Val(GTG/GTG) genotypes
as controls in different sexual or reproductive histories subgroup
(Table 4). Thus, the Ala762Ala(GCG/GCG) genotype of PARP-1
was not a significantly increased risk of developing CIN.
Polymorphism of PARP-1 and the risk of cervical
carcinoma
As shown in Table 5, the frequency of the PARP-1
Ala762Ala(GCG/GCG),Val762Ala(GTG/GCG) and Val762-
Val(GTG/GTG) genotypes were 8.5%, 59.4% and 32.1%,
respectively in controls, 19.3%, 52.5% and 28.2% in patients
with cervical carcinoma. PARP-1 Ala762Ala(GCG/GCG) carriers
in patients with cervical carcinoma were significantly higher than
those in controls (OR: 2.70, 95% CI: 1.47–3.70; P,0.001). The
distributions of these genotype frequencies in subjects with
squamous cell carcinoma were the same as those in total
carcinoma patients (OR: 2.56, 95% CI: 1.47–3.70; P,0.001).
Table 3 showed that in the HPV positive subgroup, subjects with
the PARP-1 Ala762Ala(GCG/GCG) genotype in patients with
cervical carcinoma are significantly more than those in controls
(OR: 5.56, 95% CI: 2.08–14.3; P,0.01); P,0.01]. What is more,
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subjects with the PARP-1 Ala762Ala(GCG/GCG) or Val762A-
la(GTG/GCG) genotype compared to controls in terms of the
number of sex partners (Table 6). These results indicate that
women carrying the PARP-1 Ala762Ala(GCG/GCG) genotype
had an increased risk for cervical carcinoma compared with those
carrying the PARP-1 Val762Val(GTG/GTG) genotype.
Discussion
DNA repair systems play a key role in protecting against
carcinogenesis and genetic defect in DNA repair can cause human
cancer [11]. Through repairing DNA damage and maintaining
genetic stability, PARP-1 has played an important role in
prevention of carcinogenesis. PARP-1 deficiency has enhanced
tumorigenesis and widened the tumor spectrum in tumor protein
p53-deficient mice [20]. Treatment with the alkylating agent,
azoxymethane, enhanced the frequency of tumor development in
the colon and liver of PARP-1
2/2 mice [21]. The PARP-1
Val762Ala(GTG/GCG) polymorphism has been implicated in
cancer susceptibility. It is associated with increased risk of prostate
cancer, esophageal squamous cell carcinoma, smoking-related
lung cancer and gastric cardia cancer [16–17,19–20]. In this study,
we found for the first time that the PARP-1 Ala762Ala(GCG/
GCG) genotype significantly contributes to cervical carcinoma
susceptibility, which further extend the important role of PARP-1
in carcinogenesis. Surprisingly, the PARP-1 Ala762Ala(GCG/
GCG) genotype is not associated with increased risk of developing
CIN. The majority of subjects with CIN were less than 40 years of
age, while those with cervical carcinoma were more than 40 years
of age. Thus, PARP-1 dysfunction maybe induces carcinogenesis
after the development of CIN.
Many previous studies have showed that HPV positive subjects
have a significantly increased risk of developing cervical carcinoma
compared with HPV negative ones [22–24]. Our results support
that HPV infection is a definite risk factor for cervical carcinoma,
because patients with cervical carcinoma had an about 2-fold
increased HPV infection rate compared with controls. In addition,
HPV positive subjects with the PARP-1 Ala762Ala(GCG/GCG)
genotype had stronger association with risk of cervical carcinoma,
implying that interaction of HPV infection with the genetic
variation of host jointly contributes to the cervical carcinogenesis.
The increased risk of cervical carcinoma in subjects with the
PARP-1 Ala762Ala(GCG/GCG) genotype is likely attributable to
the reduction of PARP-1 activity. PARP-1 catalyze extensive
polymerization of ADP-ribose from its substrate niconamide
adenine dinucleotide(NAD
+) to nuclear proteins, including
histones, X-ray repair cross-complementing factor-1(XRCC-1),
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-
kB), p53 and PARP-1 itself [14,25]. Residue 762 might be
implicated in the binding of substrate NAD
+, and crystal structure
of the catalytic domain of human PARP-1 reveals that 762Val is
located in the fifth helix of the PARP-1 N-terminal regulatory
subdomain, facing the pocket of the active site [26]. The recent
research show that PARP-1 762Ala displayed 57.2% of the activity
of PARP-1 762Val for auto-poly(ADP-ribosyl)ation and 61.9% of
the activity of PARP-1 762Val for trans-poly(ADP-ribosyl)ation of
histone H1, indicating that the PARP-1 Ala762 reduces the
enzymatic activity of PARP-1. Furthermore, Lockett et al. report
that the PARP-1 activity with 762Ala is decreased compared to
the PARP-1 762Val, and the PARP-1 Ala762Ala(GCG/GCG)
genotype is associated with an increased risk for prostate cancer in
Caucasian subjects [16]. Thus, 762Val-to-Ala substitution associ-
ated with reduced poly(ADP-ribosyl)ation activity, decreases
cellular repair function and therefore causes genome instability,
leading to cervical carcinoma susceptibility.
In summary, our study firstly shows a significant association
between the PARP-1 Ala762Ala(GCG/GCG) genotype and
increased risk of cervical carcinoma. Our findings suggest that
Table 6. According to different sexual or reproductive histories subgroup stratified analyses between the genotypes and cervical
carcinoma risk.
High risk exposure Controls(%) Carcinoma cases(%) Adjusted OR**(95% CI)P
TT* TC or CC* TT* TC or CC*
Number of sexual partners
#1 204(31.8) 438(68.2) 121(28.7) 301(71.3) 1.46(1.11–1.92) 0.007
.1 53(33.5) 105(66.5) 31(26.5) 86(73.5) 1.40(0.83–2.37) 0.210
Age at the first intercourse
#20 years 73(30.9) 163(69.1) 39(22.4) 135(77.6) 1.55(0.99–2.43) 0.057
.20 years 184(32.6) 380(67.4) 113(31.0) 252(68.9) 1.08(0.81–1.43) 0.595
Number of parities
#3 118(32.7) 243(67.3) 53(29.3) 128(70.7) 1.17(0.80–1.73) 0.421
.3 139(31.7) 300(68.3) 99(27.7) 259(72.3) 1.21(0.89–1.65) 0.219
Age at the first parity
#22 years 45(29.0) 110(71.0) 35(29.2) 85(70.8) 0.99(0.59–1.68) 0.981
.22 years 212(32.9) 433(67.1) 117(27.9) 302(72.1) 1.26(0.97–1.65) 0.089
Oral contraceptive
Yes 3(21.4) 11(78.6) 3(25.0) 9(75.0) 0.82(0.13–5.08) 0.830
No 254(32.3) 532(67.7) 149(28.3) 378(71.7) 1.21(0.95–1.54) 0.120
*CC: PARP-1 Ala762Ala(GCG/GCG); TC: Val762Ala(GTG/GCG); TT: Val762Val(GTG/GTG).
**all P-values adjusted for age.
doi:10.1371/journal.pone.0037446.t006
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